• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
MYX 1.06% $4.68

MAYNE PHARMA GROUP LIMITED - Announcements

Mayne Pharma Group Limited is an Australia-based specialty pharmaceutical company focused... Mayne Pharma Group Limited is an Australia-based specialty pharmaceutical company focused on commercializing novel pharmaceuticals. The Company also provides contract development and manufacturing services to clients worldwide. The Company’s segments include Women’s Health, Dermatology, and International. The Women’s Health segment distributes women’s health branded products in the United States. This segment includes NEXTSTELLIS, ANNOVERA, BIJUVA, IMVEXXY and branded pre-natal vitamins. The Dermatology segment distributes established dermatology products in the United States. The International segment is engaged in the manufacture and sale of branded and generic pharmaceutical products globally and the provision of contract development and manufacturing services to third party customers. The Company's products include ACTIKERALL Solution, ASTRIX Capsules and Tablets, MAGNOPLASM Paste and SPLINTEX Splinter Removal Gel, and ANNOVERA Vaginal Ring, among others.More

Announcements


Filters [Clear]
  • Price Sensitive: Yes
MYX Class action settlementPRICE SENSITIVE02/07/24 download Created with Sketch. 90.31KB
MYX Notification of buy-back - MYXPRICE SENSITIVE24/05/24 download Created with Sketch. 13.03KB
MYX 2024 Half Year Investor PresentationPRICE SENSITIVE26/02/24 download Created with Sketch. 1.1MB
MYX 2024 Half Year Media ReleasePRICE SENSITIVE26/02/24 download Created with Sketch. 337.33KB
MYX Half Yearly Report and AccountsPRICE SENSITIVE26/02/24 download Created with Sketch. 1.3MB
MYX Issuance of additional US Patent for NEXTSTELLISPRICE SENSITIVE06/11/23 download Created with Sketch. 124.22KB
MYX Mayne Pharma provides update on 1Q FY24 trading and outlookPRICE SENSITIVE18/10/23 download Created with Sketch. 969.53KB
MYX 2023 Full Year Results Investor PresentationPRICE SENSITIVE31/08/23 download Created with Sketch. 1.07MB
MYX 2023 Full Year Results Media ReleasePRICE SENSITIVE31/08/23 download Created with Sketch. 159.25KB
MYX Preliminary Final ReportPRICE SENSITIVE31/08/23 download Created with Sketch. 1.23MB
MYX Mayne Pharma May 2023 market update presentationPRICE SENSITIVE10/05/23 download Created with Sketch. 1.26MB
MYX MYX provides investor update & announces on market buybackPRICE SENSITIVE10/05/23 download Created with Sketch. 175.1KB
MYX MYX completes sale of US retail generics business for US$90mPRICE SENSITIVE11/04/23 download Created with Sketch. 126.41KB
MYX Update on sale of US retail generics portfolioPRICE SENSITIVE03/04/23 download Created with Sketch. 90.76KB
MYX Mayne Pharma announces cancellation of capital returnPRICE SENSITIVE28/02/23 download Created with Sketch. 88.17KB
MYX 2023 Half Year Investor PresentationPRICE SENSITIVE28/02/23 download Created with Sketch. 2.17MB
MYX 2022 Half Year Media ReleasePRICE SENSITIVE28/02/23 download Created with Sketch. 188.04KB
MYX Half Yearly Report and AccountsPRICE SENSITIVE28/02/23 download Created with Sketch. 1.25MB
MYX Mayne Pharma announces sale of US retail generics businessPRICE SENSITIVE27/02/23 download Created with Sketch. 152.88KB
MYX Trading HaltPRICE SENSITIVE27/02/23 download Created with Sketch. 248.55KB
MYX Pause in TradingPRICE SENSITIVE27/02/23 download Created with Sketch. 117.29KB
MYX Mayne Pharma to restate US dermatology net revenue for FY22PRICE SENSITIVE15/02/23 download Created with Sketch. 126.64KB
MYX Mayne Pharma provides update on capital management timelinePRICE SENSITIVE12/01/23 download Created with Sketch. 151.54KB
MYX MYX completes TherapeuticsMD product licensing transactionPRICE SENSITIVE03/01/23 download Created with Sketch. 108.26KB
MYX MYX signs license agreement for women's health productsPRICE SENSITIVE05/12/22 download Created with Sketch. 186.17KB
MYX AGM presentation and business and trading updatePRICE SENSITIVE30/11/22 download Created with Sketch. 985.21KB
MYX Return of Capital - MYXPRICE SENSITIVE28/10/22 download Created with Sketch. 151.27KB
MYX Dividend/Distribution - MYXPRICE SENSITIVE28/10/22 download Created with Sketch. 194KB
MYX Mayne Pharma capital management updatePRICE SENSITIVE28/10/22 download Created with Sketch. 156.76KB
MYX Mayne Pharma completes sale of Metrics Contract ServicesPRICE SENSITIVE04/10/22 download Created with Sketch. 162.72KB
MYX Mayne Pharma appoints new CEOPRICE SENSITIVE28/09/22 download Created with Sketch. 160.07KB
MYX 2022 Full Year Investor PresentationPRICE SENSITIVE26/08/22 download Created with Sketch. 2.74MB
MYX 2022 Full Year Media ReleasePRICE SENSITIVE26/08/22 download Created with Sketch. 393.2KB
MYX Appendix 4E and Statutory AccountsPRICE SENSITIVE26/08/22 download Created with Sketch. 2.08MB
MYX Mayne Pharma CEO announces plan to retirePRICE SENSITIVE19/08/22 download Created with Sketch. 147.48KB
MYX Mayne Pharma announces sale of Metrics Contract ServicesPRICE SENSITIVE10/08/22 download Created with Sketch. 189.91KB
MYX Mayne Pharma recipient of $4.8m Federal Government GrantPRICE SENSITIVE09/05/22 download Created with Sketch. 95.11KB
MYX 2022 Half Year Investor PresentationPRICE SENSITIVE25/02/22 download Created with Sketch. 1.71MB
MYX 2022 Half Year Media ReleasePRICE SENSITIVE25/02/22 download Created with Sketch. 323.7KB
MYX Half Yearly Report and AccountsPRICE SENSITIVE25/02/22 download Created with Sketch. 4.6MB
MYX Mayne Pharma expands US dermatology portfolioPRICE SENSITIVE10/02/22 download Created with Sketch. 94.58KB
MYX 2021 Mayne Pharma AGM SpeechesPRICE SENSITIVE23/11/21 download Created with Sketch. 948.24KB
MYX 2021 Full Year Investor PresentationPRICE SENSITIVE27/08/21 download Created with Sketch. 1.13MB
MYX 2021 Full Year Media ReleasePRICE SENSITIVE27/08/21 download Created with Sketch. 395.94KB
MYX Appendix 4E and Statutory AccountsPRICE SENSITIVE27/08/21 download Created with Sketch. 1.97MB
MYX Class action proceedingPRICE SENSITIVE03/08/21 download Created with Sketch. 114.64KB
MYX FDA approval of novel oral contraceptive NEXTSTELLISPRICE SENSITIVE16/04/21 download Created with Sketch. 123.85KB
MYX 2021 Half Year Investor PresentationPRICE SENSITIVE24/02/21 download Created with Sketch. 2.76MB
MYX 2021 Half Year Media ReleasePRICE SENSITIVE24/02/21 download Created with Sketch. 314.02KB
MYX Half Yearly Report and AccountsPRICE SENSITIVE24/02/21 download Created with Sketch. 1.76MB
MYX Chairman and CEO's Addresses to ShareholdersPRICE SENSITIVE24/11/20 download Created with Sketch. 3.27MB
MYX Mayne Pharma provides update on Women's Health pipelinePRICE SENSITIVE06/10/20 download Created with Sketch. 153.98KB
MYX 2020 Full Year Investor PresentationPRICE SENSITIVE21/08/20 download Created with Sketch. 6.13MB
MYX 2020 Full Year Media ReleasePRICE SENSITIVE21/08/20 download Created with Sketch. 404.79KB
MYX Appendix 4E and Statutory AccountsPRICE SENSITIVE21/08/20 download Created with Sketch. 1.59MB
MYX Mayne Pharma announces strategic partnership with NovastPRICE SENSITIVE06/07/20 download Created with Sketch. 158.24KB
MYX MYX announces FDA filing acceptance of E4/DRSP in the USPRICE SENSITIVE24/06/20 download Created with Sketch. 149.82KB
MYX S&P DJI Announces June 2020 Quarterly RebalancePRICE SENSITIVE12/06/20 download Created with Sketch. 223.16KB
MYX MYX signs license agreement for contraceptive in AustraliaPRICE SENSITIVE28/05/20 download Created with Sketch. 150.15KB
MYX Mayne Pharma submits NDA for E4/DRSP to the FDAPRICE SENSITIVE16/04/20 download Created with Sketch. 121.21KB
MYX 2020 Half Year Investor PresentationPRICE SENSITIVE21/02/20 download Created with Sketch. 3.5MB
MYX 2020 Half Year Media ReleasePRICE SENSITIVE21/02/20 download Created with Sketch. 325.33KB
MYX Half Yearly Report and AccountsPRICE SENSITIVE21/02/20 download Created with Sketch. 1.11MB
MYX 2019 AGM CEO's SpeechPRICE SENSITIVE22/11/19 download Created with Sketch. 138.92KB
MYX E4/DRSP contraceptive presented at EU gynecology conferencePRICE SENSITIVE23/10/19 download Created with Sketch. 110.39KB
MYX MYX signs license agreement for novel oral contraceptivePRICE SENSITIVE02/10/19 download Created with Sketch. 126.01KB
MYX 2019 Full Year Results Investor PresentationPRICE SENSITIVE23/08/19 download Created with Sketch. 1.14MB
MYX 2019 Full Year Results Media ReleasePRICE SENSITIVE23/08/19 download Created with Sketch. 174.98KB
MYX Appendix 4E and Full Year Statutory AccountsPRICE SENSITIVE23/08/19 download Created with Sketch. 1.71MB
MYX Mayne Pharma market updatePRICE SENSITIVE14/05/19 download Created with Sketch. 286.05KB
MYX 2019 Half Year Investor PresentationPRICE SENSITIVE22/02/19 download Created with Sketch. 1.44MB
MYX 2019 Half Year Media ReleasePRICE SENSITIVE22/02/19 download Created with Sketch. 439.98KB
MYX Half Year AccountsPRICE SENSITIVE22/02/19 download Created with Sketch. 1.44MB
MYX Tolsura (SUBA-itraconazole) capsule now launched in the USPRICE SENSITIVE30/01/19 download Created with Sketch. 455.75KB
MYX FDA approval of Tolsura (SUBA-itraconazole) capsulesPRICE SENSITIVE12/12/18 download Created with Sketch. 409.5KB
MYX 2018 AGM CEO's SpeechPRICE SENSITIVE29/11/18 download Created with Sketch. 256.36KB
MYX 2018 AGM Chairman's AddressPRICE SENSITIVE29/11/18 download Created with Sketch. 257.21KB
MYX 2018 Full Year Results Investor PresentationPRICE SENSITIVE24/08/18 download Created with Sketch. 1.43MB
MYX 2018 Full Year Results Media ReleasePRICE SENSITIVE24/08/18 download Created with Sketch. 444.47KB
MYX Full Year Statutory AccountsPRICE SENSITIVE24/08/18 download Created with Sketch. 7.43MB
MYX Mayne Pharma acquires generic Efudex in the USPRICE SENSITIVE23/07/18 download Created with Sketch. 269.46KB
MYX SUBA-Itraconazole NDA accepted for review by US FDAPRICE SENSITIVE02/05/18 download Created with Sketch. 390.44KB
MYX Mayne Pharma opens new US manufacturing facilityPRICE SENSITIVE18/04/18 download Created with Sketch. 267.75KB
MYX Mayne Pharma launches Amiodarone 200mg tablets in the USPRICE SENSITIVE17/04/18 download Created with Sketch. 256.29KB
MYX Mayne Pharma's generic NuvaRing accepted for filing by FDAPRICE SENSITIVE20/03/18 download Created with Sketch. 391.96KB
MYX Mayne Pharma launches doxycycline IR capsules in the USPRICE SENSITIVE16/03/18 download Created with Sketch. 383.19KB
MYX First generic launch of Ritalin LA 10mg capsules in the USPRICE SENSITIVE01/03/18 download Created with Sketch. 98.7KB
MYX 2018 Half Year Investor PresentationPRICE SENSITIVE23/02/18 download Created with Sketch. 1.74MB
MYX 2018 Half Year Media ReleasePRICE SENSITIVE23/02/18 download Created with Sketch. 437.47KB
MYX Half Yearly Report and AccountsPRICE SENSITIVE23/02/18 download Created with Sketch. 1.4MB
MYX 2017 CEO's SpeechPRICE SENSITIVE28/11/17 download Created with Sketch. 297.96KB
MYX Mayne Pharma launches clozapine tablets in the USPRICE SENSITIVE09/11/17 download Created with Sketch. 247.68KB
MYX Mayne Pharma adds two products to its Australian portfolioPRICE SENSITIVE15/09/17 download Created with Sketch. 427.72KB
MYX Preliminary Final ReportPRICE SENSITIVE25/08/17 download Created with Sketch. 1.5MB
MYX Mayne Pharma market updatePRICE SENSITIVE08/08/17 download Created with Sketch. 447.89KB
MYX FDA approval and first generic launch of Acticlate tabletsPRICE SENSITIVE15/06/17 download Created with Sketch. 96.5KB
MYX Response to ASX Aware LetterPRICE SENSITIVE04/05/17 download Created with Sketch. 653.95KB
MYX Clarification statementPRICE SENSITIVE02/05/17 download Created with Sketch. 89.14KB
MYX Mayne Pharma acquires rights to generic Duragesic in the USPRICE SENSITIVE09/03/17 download Created with Sketch. 268.96KB
MYX License and supply agreement for generic Nuvaring in the USPRICE SENSITIVE28/02/17 download Created with Sketch. 103.27KB
MYX Class action settlement
02/07/24PRICE SENSITIVE download Created with Sketch. 90.31KB
MYX Notification of buy-back - MYX
24/05/24PRICE SENSITIVE download Created with Sketch. 13.03KB
MYX 2024 Half Year Investor Presentation
26/02/24PRICE SENSITIVE download Created with Sketch. 1.1MB
MYX 2024 Half Year Media Release
26/02/24PRICE SENSITIVE download Created with Sketch. 337.33KB
MYX Half Yearly Report and Accounts
26/02/24PRICE SENSITIVE download Created with Sketch. 1.3MB
MYX Issuance of additional US Patent for NEXTSTELLIS
06/11/23PRICE SENSITIVE download Created with Sketch. 124.22KB
MYX Mayne Pharma provides update on 1Q FY24 trading and outlook
18/10/23PRICE SENSITIVE download Created with Sketch. 969.53KB
MYX 2023 Full Year Results Investor Presentation
31/08/23PRICE SENSITIVE download Created with Sketch. 1.07MB
MYX 2023 Full Year Results Media Release
31/08/23PRICE SENSITIVE download Created with Sketch. 159.25KB
MYX Preliminary Final Report
31/08/23PRICE SENSITIVE download Created with Sketch. 1.23MB
MYX Mayne Pharma May 2023 market update presentation
10/05/23PRICE SENSITIVE download Created with Sketch. 1.26MB
MYX MYX provides investor update & announces on market buyback
10/05/23PRICE SENSITIVE download Created with Sketch. 175.1KB
MYX MYX completes sale of US retail generics business for US$90m
11/04/23PRICE SENSITIVE download Created with Sketch. 126.41KB
MYX Update on sale of US retail generics portfolio
03/04/23PRICE SENSITIVE download Created with Sketch. 90.76KB
MYX Mayne Pharma announces cancellation of capital return
28/02/23PRICE SENSITIVE download Created with Sketch. 88.17KB
MYX 2023 Half Year Investor Presentation
28/02/23PRICE SENSITIVE download Created with Sketch. 2.17MB
MYX 2022 Half Year Media Release
28/02/23PRICE SENSITIVE download Created with Sketch. 188.04KB
MYX Half Yearly Report and Accounts
28/02/23PRICE SENSITIVE download Created with Sketch. 1.25MB
MYX Mayne Pharma announces sale of US retail generics business
27/02/23PRICE SENSITIVE download Created with Sketch. 152.88KB
MYX Trading Halt
27/02/23PRICE SENSITIVE download Created with Sketch. 248.55KB
MYX Pause in Trading
27/02/23PRICE SENSITIVE download Created with Sketch. 117.29KB
MYX Mayne Pharma to restate US dermatology net revenue for FY22
15/02/23PRICE SENSITIVE download Created with Sketch. 126.64KB
MYX Mayne Pharma provides update on capital management timeline
12/01/23PRICE SENSITIVE download Created with Sketch. 151.54KB
MYX MYX completes TherapeuticsMD product licensing transaction
03/01/23PRICE SENSITIVE download Created with Sketch. 108.26KB
MYX MYX signs license agreement for women's health products
05/12/22PRICE SENSITIVE download Created with Sketch. 186.17KB
MYX AGM presentation and business and trading update
30/11/22PRICE SENSITIVE download Created with Sketch. 985.21KB
MYX Return of Capital - MYX
28/10/22PRICE SENSITIVE download Created with Sketch. 151.27KB
MYX Dividend/Distribution - MYX
28/10/22PRICE SENSITIVE download Created with Sketch. 194KB
MYX Mayne Pharma capital management update
28/10/22PRICE SENSITIVE download Created with Sketch. 156.76KB
MYX Mayne Pharma completes sale of Metrics Contract Services
04/10/22PRICE SENSITIVE download Created with Sketch. 162.72KB
MYX Mayne Pharma appoints new CEO
28/09/22PRICE SENSITIVE download Created with Sketch. 160.07KB
MYX 2022 Full Year Investor Presentation
26/08/22PRICE SENSITIVE download Created with Sketch. 2.74MB
MYX 2022 Full Year Media Release
26/08/22PRICE SENSITIVE download Created with Sketch. 393.2KB
MYX Appendix 4E and Statutory Accounts
26/08/22PRICE SENSITIVE download Created with Sketch. 2.08MB
MYX Mayne Pharma CEO announces plan to retire
19/08/22PRICE SENSITIVE download Created with Sketch. 147.48KB
MYX Mayne Pharma announces sale of Metrics Contract Services
10/08/22PRICE SENSITIVE download Created with Sketch. 189.91KB
MYX Mayne Pharma recipient of $4.8m Federal Government Grant
09/05/22PRICE SENSITIVE download Created with Sketch. 95.11KB
MYX 2022 Half Year Investor Presentation
25/02/22PRICE SENSITIVE download Created with Sketch. 1.71MB
MYX 2022 Half Year Media Release
25/02/22PRICE SENSITIVE download Created with Sketch. 323.7KB
MYX Half Yearly Report and Accounts
25/02/22PRICE SENSITIVE download Created with Sketch. 4.6MB
MYX Mayne Pharma expands US dermatology portfolio
10/02/22PRICE SENSITIVE download Created with Sketch. 94.58KB
MYX 2021 Mayne Pharma AGM Speeches
23/11/21PRICE SENSITIVE download Created with Sketch. 948.24KB
MYX 2021 Full Year Investor Presentation
27/08/21PRICE SENSITIVE download Created with Sketch. 1.13MB
MYX 2021 Full Year Media Release
27/08/21PRICE SENSITIVE download Created with Sketch. 395.94KB
MYX Appendix 4E and Statutory Accounts
27/08/21PRICE SENSITIVE download Created with Sketch. 1.97MB
MYX Class action proceeding
03/08/21PRICE SENSITIVE download Created with Sketch. 114.64KB
MYX FDA approval of novel oral contraceptive NEXTSTELLIS
16/04/21PRICE SENSITIVE download Created with Sketch. 123.85KB
MYX 2021 Half Year Investor Presentation
24/02/21PRICE SENSITIVE download Created with Sketch. 2.76MB
MYX 2021 Half Year Media Release
24/02/21PRICE SENSITIVE download Created with Sketch. 314.02KB
MYX Half Yearly Report and Accounts
24/02/21PRICE SENSITIVE download Created with Sketch. 1.76MB
MYX Chairman and CEO's Addresses to Shareholders
24/11/20PRICE SENSITIVE download Created with Sketch. 3.27MB
MYX Mayne Pharma provides update on Women's Health pipeline
06/10/20PRICE SENSITIVE download Created with Sketch. 153.98KB
MYX 2020 Full Year Investor Presentation
21/08/20PRICE SENSITIVE download Created with Sketch. 6.13MB
MYX 2020 Full Year Media Release
21/08/20PRICE SENSITIVE download Created with Sketch. 404.79KB
MYX Appendix 4E and Statutory Accounts
21/08/20PRICE SENSITIVE download Created with Sketch. 1.59MB
MYX Mayne Pharma announces strategic partnership with Novast
06/07/20PRICE SENSITIVE download Created with Sketch. 158.24KB
MYX MYX announces FDA filing acceptance of E4/DRSP in the US
24/06/20PRICE SENSITIVE download Created with Sketch. 149.82KB
MYX S&P DJI Announces June 2020 Quarterly Rebalance
12/06/20PRICE SENSITIVE download Created with Sketch. 223.16KB
MYX MYX signs license agreement for contraceptive in Australia
28/05/20PRICE SENSITIVE download Created with Sketch. 150.15KB
MYX Mayne Pharma submits NDA for E4/DRSP to the FDA
16/04/20PRICE SENSITIVE download Created with Sketch. 121.21KB
MYX 2020 Half Year Investor Presentation
21/02/20PRICE SENSITIVE download Created with Sketch. 3.5MB
MYX 2020 Half Year Media Release
21/02/20PRICE SENSITIVE download Created with Sketch. 325.33KB
MYX Half Yearly Report and Accounts
21/02/20PRICE SENSITIVE download Created with Sketch. 1.11MB
MYX 2019 AGM CEO's Speech
22/11/19PRICE SENSITIVE download Created with Sketch. 138.92KB
MYX E4/DRSP contraceptive presented at EU gynecology conference
23/10/19PRICE SENSITIVE download Created with Sketch. 110.39KB
MYX MYX signs license agreement for novel oral contraceptive
02/10/19PRICE SENSITIVE download Created with Sketch. 126.01KB
MYX 2019 Full Year Results Investor Presentation
23/08/19PRICE SENSITIVE download Created with Sketch. 1.14MB
MYX 2019 Full Year Results Media Release
23/08/19PRICE SENSITIVE download Created with Sketch. 174.98KB
MYX Appendix 4E and Full Year Statutory Accounts
23/08/19PRICE SENSITIVE download Created with Sketch. 1.71MB
MYX Mayne Pharma market update
14/05/19PRICE SENSITIVE download Created with Sketch. 286.05KB
MYX 2019 Half Year Investor Presentation
22/02/19PRICE SENSITIVE download Created with Sketch. 1.44MB
MYX 2019 Half Year Media Release
22/02/19PRICE SENSITIVE download Created with Sketch. 439.98KB
MYX Half Year Accounts
22/02/19PRICE SENSITIVE download Created with Sketch. 1.44MB
MYX Tolsura (SUBA-itraconazole) capsule now launched in the US
30/01/19PRICE SENSITIVE download Created with Sketch. 455.75KB
MYX FDA approval of Tolsura (SUBA-itraconazole) capsules
12/12/18PRICE SENSITIVE download Created with Sketch. 409.5KB
MYX 2018 AGM CEO's Speech
29/11/18PRICE SENSITIVE download Created with Sketch. 256.36KB
MYX 2018 AGM Chairman's Address
29/11/18PRICE SENSITIVE download Created with Sketch. 257.21KB
MYX 2018 Full Year Results Investor Presentation
24/08/18PRICE SENSITIVE download Created with Sketch. 1.43MB
MYX 2018 Full Year Results Media Release
24/08/18PRICE SENSITIVE download Created with Sketch. 444.47KB
MYX Full Year Statutory Accounts
24/08/18PRICE SENSITIVE download Created with Sketch. 7.43MB
MYX Mayne Pharma acquires generic Efudex in the US
23/07/18PRICE SENSITIVE download Created with Sketch. 269.46KB
MYX SUBA-Itraconazole NDA accepted for review by US FDA
02/05/18PRICE SENSITIVE download Created with Sketch. 390.44KB
MYX Mayne Pharma opens new US manufacturing facility
18/04/18PRICE SENSITIVE download Created with Sketch. 267.75KB
MYX Mayne Pharma launches Amiodarone 200mg tablets in the US
17/04/18PRICE SENSITIVE download Created with Sketch. 256.29KB
MYX Mayne Pharma's generic NuvaRing accepted for filing by FDA
20/03/18PRICE SENSITIVE download Created with Sketch. 391.96KB
MYX Mayne Pharma launches doxycycline IR capsules in the US
16/03/18PRICE SENSITIVE download Created with Sketch. 383.19KB
MYX First generic launch of Ritalin LA 10mg capsules in the US
01/03/18PRICE SENSITIVE download Created with Sketch. 98.7KB
MYX 2018 Half Year Investor Presentation
23/02/18PRICE SENSITIVE download Created with Sketch. 1.74MB
MYX 2018 Half Year Media Release
23/02/18PRICE SENSITIVE download Created with Sketch. 437.47KB
MYX Half Yearly Report and Accounts
23/02/18PRICE SENSITIVE download Created with Sketch. 1.4MB
MYX 2017 CEO's Speech
28/11/17PRICE SENSITIVE download Created with Sketch. 297.96KB
MYX Mayne Pharma launches clozapine tablets in the US
09/11/17PRICE SENSITIVE download Created with Sketch. 247.68KB
MYX Mayne Pharma adds two products to its Australian portfolio
15/09/17PRICE SENSITIVE download Created with Sketch. 427.72KB
MYX Preliminary Final Report
25/08/17PRICE SENSITIVE download Created with Sketch. 1.5MB
MYX Mayne Pharma market update
08/08/17PRICE SENSITIVE download Created with Sketch. 447.89KB
MYX FDA approval and first generic launch of Acticlate tablets
15/06/17PRICE SENSITIVE download Created with Sketch. 96.5KB
MYX Response to ASX Aware Letter
04/05/17PRICE SENSITIVE download Created with Sketch. 653.95KB
MYX Clarification statement
02/05/17PRICE SENSITIVE download Created with Sketch. 89.14KB
MYX Mayne Pharma acquires rights to generic Duragesic in the US
09/03/17PRICE SENSITIVE download Created with Sketch. 268.96KB
MYX License and supply agreement for generic Nuvaring in the US
28/02/17PRICE SENSITIVE download Created with Sketch. 103.27KB
(20min delay)
Last
$4.68
Change
-0.050(1.06%)
Mkt cap ! $398.1M
Open High Low Value Volume
$4.67 $4.76 $4.65 $606.2K 128.8K

Buyers (Bids)

No. Vol. Price($)
1 48 $4.68
 

Sellers (Offers)

Price($) Vol. No.
$4.70 105 1
View Market Depth
Last trade - 16.10pm 22/07/2024 (20 minute delay) ?
Last
$4.69
  Change
-0.050 ( 0.52 %)
Open High Low Volume
$4.62 $4.76 $4.62 29282
Last updated 15.59pm 22/07/2024 ?
MYX (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.